7News Just In7News Just In

New weight loss pill outperforms rivals but causes side effects

View descriptionShare
A new daily weight loss pill called orforglipron, manufactured by Eli Lilly, has demonstrated superior results to Wegovy in a clinical trial of over 1,500 adults with type 2 diabetes across five countries. After 12 months, participants taking orforglipron experienced 6-8% weight loss compared to 4-5% with oral semaglutide, along with bigger drops in average blood sugar levels. However, orforglipron caused more severe gastrointestinal side effects including vomiting and diarrhoea, leading up to 10% of trial participants to discontinue use, and the medication is still awaiting regulatory approval in Australia.
 
  • Facebook
  • X (Twitter)
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

7News Just In

7News Just In is a daily podcast that brings you Australia's latest news. 
Social links
Follow podcast
Recent clips
Browse 1,636 clip(s)